Amneal Pharmaceuticals Cash Flow Statement
NASDAQ: AMRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amneal Pharmaceuticals free cash flow
In fiscal 2025, Amneal Pharmaceuticals generated $340.0 million of operating cash flow and spent $70.1 million on capital expenditures. That left free cash flow of $269.9 million, a free-cash-flow margin of 8.9% of revenue. Free cash flow was up 11.0% from the prior year's $243.2 million.
Summary generated from market data by MetaCap's automated system. Methodology
Amneal Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 127.93M | -73.88M | -48.72M | -254.79M | 20.17M | 68.58M | -603.57M | -201.30M | 169.32M | 209.43M |
| Net Income growth (YoY) | — | — | — | -1363.21% | -70.59% | — | — | -218.89% | -19.15% | — |
| Depreciation & Amortization | 57.30M | 62.60M | 66.20M | 68.10M | 60.70M | 60.42M | 63.28M | 64.42M | 41.96M | 29.31M |
| Stock-Based Compensation | 31.95M | 27.77M | 26.82M | 31.85M | 28.41M | 20.75M | 21.68M | 167.60M | 0 | 0 |
| Change in Working Capital | -205.43M | -58.99M | -56.52M | -62.66M | -138.55M | -63.38M | -124.51M | 2.29M | -3.77M | -156.76M |
| Operating Cash Flow | 339.99M | 295.10M | 345.58M | 65.10M | 241.82M | 379.00M | 1.71M | 250.23M | 234.19M | 115.06M |
| Capital Expenditures | -70.06M | -51.92M | -43.22M | -46.41M | -47.73M | -56.45M | -47.18M | -83.09M | -94.77M | -122.76M |
| Investing Cash Flow | -112.26M | -63.00M | -69.19M | -174.31M | -194.18M | -317.55M | -19.58M | -396.38M | -98.55M | -124.61M |
| Dividends Paid | — | — | — | — | — | 0 | 0 | -183.00M | -375.26M | -200.62M |
| Share Repurchases | — | — | — | — | — | — | — | — | — | -5.00K |
| Debt Issued | 2.69B | 0 | 217.73M | 0 | 0 | — | — | — | — | — |
| Financing Cash Flow | -31.53M | -211.79M | -212.57M | -106.62M | -138.12M | 131.81M | -45.83M | 287.68M | -95.02M | -19.50M |
| Net Change in Cash | 194.52M | 19.31M | 63.88M | -221.51M | -90.38M | 194.30M | -65.96M | 140.86M | 40.38M | -27.56M |
| Free Cash Flow | 269.93M | 243.18M | 302.36M | 18.69M | 194.09M | 322.56M | -45.48M | 167.14M | 139.42M | -7.70M |
This table shows 10 annual periods of Amneal Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AMRX's reporting calendar. What is a cash flow statement?